Two interesting points are raised by Drs Khurana and Khurana about our study in CHEST (May 2010).
host responses, including the immune assays currently used for diagnosis of latent TB infection, are needed.
Caroline J. Gallant 
Is Pulmonary Arterial Hypertension Really a Late Complication of Systemic Sclerosis?
To the Editor:
We read with great interest the report by Hachulla et al in CHEST (May 2009) 1 regarding the time of presentation of pulmonary arterial hypertension (PAH) during the course of scleroderma disease (SSc). In their cohort of 78 patients with SScassociated PAH (PAH-SSc), the authors found the following: (1) 55% of the patients had early-onset PAH (ie, within the fi rst 5 years of SSc-related non-Raynaud symptoms); (2) These patients were older at the time of SSc diagnosis and presented with more severe hemodynamics, although functional class (FC) and mortality outcomes were similar to those of patients with lateonset PAH; (3) Diffusing capacity of the lung for carbon monoxide (D lco) , 35% and FC class 4 were the only predictors for survival 
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The correspondence by Campo et al regarding our recent publication in CHEST (November 2009) 1 emphasizing that systemic sclerosis-associated pulmonary arterial hypertension (PAH-SSc) may occur early in the course of the disease (ie, within the fi rst 5 years of systemic sclerosis [SSc]-related, non-Raynaud phenomenon symptoms) is of great interest. Indeed, for the fi rst time, two teams, one in the European Union and one in the United States, independently have shown that PAH-SSc may be an early complication of SSc in up to one-half of the cases. As a consequence, we both recommend that screening for pulmonary arterial hypertension (PAH) should be considered immediately after the occurrence of the fi rst SSc-related non-Raynaud phenomenon symptom.
Campo et al then focus their discussion on the threshold of the diffusion capacity of carbon monoxide (D lco ) (35% of predicted value) that we have found to be an independent risk of death in our population of patients with PAH-SSc (hazard ratio, 2.587; 95% CI, 1.029 -6.501; P 5 .04). Obviously, D lco may be reduced not only because of pulmonary vascular disease but also because of comorbid interstitial lung disease (ILD), which is not uncommon in such patients. Distinguishing pure PAH from pulmonary hypertension (PH) due to hypoxia associated with lung fi brosis in patients with SSc may be challenging, and both conditions are sometimes associated. Patients with evidence of ILD, as demonstrated by abnormal high-resolution CT scans of the chest and total lung capacity (TLC) ranging from 60% to 70% with elevated mean pulmonary arterial pressure . 25 mm Hg at rest, were kept in the analysis set in case of the absence of extensive ILD or severe lung fi brosis, based on the expertise of our team, because they were considered more likely to have PAH-SSc rather than ILD-associated PH.
We agree that such patients may be diffi cult to classify and that some may have quite severe ILD, which could contribute to PH. In order to address this comment, we have reanalyzed our data after exclusion of all patients with a TLC , 70% and found a 40% cutoff of predicted D lco value to be an independent risk of death at 3 years in patients with PAH-SSc (hazard ratio, 11.25; 95% CI, 1.38 -91.60; P 5 .02). These consistent results suggest in this cohort; and (4) There was a relatively high proportion (22%) of patients with diffuse subtype SSc (dSSc).
We recently described survival outcomes of a cohort of 76 patients with PAH-SSc followed at our center. 2 Although the proportion of early-onset PAH in our cohort was lower (36%), 25% of these patients were diagnosed with PAH within the fi rst 3 years and 11% within the same year of SSc diagnosis. Similar to fi ndings by Hachulla et al, 1 our patients with early-onset PAH were older at the time of SSc presentation compared with patients developing PAH later (59 vs 43 years; P , .01); however, there were no differences in hemodynamics or survival between the groups. Nonetheless, fi ndings from both studies reinforce the need for early screening for PAH in these patients.
In addition, in the study by Hachulla et al, 1 D lco , 35% and FC were the only predictors for survival. This fi nding may be biased by inclusion of patients with more than mild interstitial lung disease (ILD), because criteria for excluding ILD were based only on FVC or total lung capacity , 60% without consideration of radiologic fi ndings.
3 ILD clearly has an impact on survival in SSc, 3 in particular when complicated by pulmonary hypertension, as recently demonstrated.
4 , 5 Thus, one cannot exclude the fact that poorer outcomes related to D lco , 35% might refl ect more signifi cant ILD than suggested by pulmonary function tests alteration alone. In this context, the relatively high proportion of patients with dSSc (22%), compared with other studies of PAH-SSc (8%-13%) 6 , 7 with stricter criteria for ILD exclusion, may indicate inclusion of patients with signifi cant ILD (more common with this SSc subtype). In summary, we wish to emphasize the need for a rigorous phenotypic characterization in order to identify the exact factors responsible for very poor outcomes in PAH-SSc, while avoiding confounders.
